Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that is characterized by progressive airway obstruction that, unlike asthma, is relatively insensitive to bronchodilators and to the classic anti-inflammatory therapy, corticosteroids. In this review we consider the poten...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2007-06, Vol.12 (11), p.472-478
Main Authors: Fitzgerald, Mary F., Fox, J. Craig
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Adrenergic beta-Agonists - therapeutic use
Animals
Anti-Inflammatory Agents - therapeutic use
Biological and medical sciences
Bronchodilator Agents - therapeutic use
Chronic obstructive pulmonary disease, asthma
Drug Therapy, Combination
Humans
Medical sciences
Muscarinic Antagonists - therapeutic use
Pharmacology. Drug treatments
Pneumology
Pulmonary Disease, Chronic Obstructive - drug therapy
Respiratory system
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that is characterized by progressive airway obstruction that, unlike asthma, is relatively insensitive to bronchodilators and to the classic anti-inflammatory therapy, corticosteroids. In this review we consider the potential of bronchodilator drugs and corticosteroid drugs that are in clinical development for COPD and discuss how the best treatments might be achieved with combinations of drugs that are either already launched or close to launch.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2007.04.003